What's Happening?
Eli Lilly has decided to terminate its partnership with Rigel Pharmaceuticals, effective June 15, 2026. This decision involves the return of rights to two investigational RIPK1 inhibitors to Rigel, as detailed in a recent SEC filing. The collaboration,
which began in February 2021, initially involved a $125 million investment from Lilly for licensing the RIPK1 blockers, with potential milestones and royalties amounting to $835 million. The partnership's progress has been limited, with Lilly previously discontinuing a central nervous system program in 2025. The remaining asset, ocadusertib, is currently in a mid-stage trial for rheumatoid arthritis. The broader RIPK1 inhibitor field has seen setbacks, with other major companies like Sanofi and Roche also halting similar projects due to disappointing results.
Why It's Important?
The termination of this partnership highlights ongoing challenges in the development of RIPK1 inhibitors, a drug class aimed at regulating inflammation and cell death. This decision reflects a broader industry trend of moving away from RIPK1 inhibitors due to underwhelming clinical outcomes. For Rigel Pharmaceuticals, regaining full rights to the compounds presents both an opportunity and a challenge, as they must now decide on the future of these assets without Lilly's support. The move could impact Rigel's financial outlook and strategic direction, while also influencing investor confidence in the viability of RIPK1 inhibitors as a therapeutic approach.
What's Next?
Rigel Pharmaceuticals will need to assess the financial and strategic implications of Eli Lilly's withdrawal. The company may explore new partnerships or alternative development strategies for the RIPK1 inhibitors. The ongoing trial for ocadusertib in rheumatoid arthritis remains a critical focus, with its outcome potentially influencing future decisions. Industry observers will be watching to see if Rigel can successfully advance these assets independently or if they will seek new collaborations to support further development.
